FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2019/06/019745 [Registered on: 18/06/2019] Trial Registered Prospectively
Last Modified On: 17/06/2019
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Use of swashahara mahakashaya avleha in childhood bronchial asthma 
Scientific Title of Study   A Comparative Study to Evaluate the Efficacy of Shwasahara Mahakashaya Avleha w.r.to Shwasahara Mahakashaya choorna in Tamaka Shwasa w.s.r to Childhood Bronchial Asthma–An open ended, double armed, Randomized, Controlled Clinical Trial. 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  jitendra kumar acharya 
Designation  PG Scholar 
Affiliation  All India Institute of Ayurveda New Delhi 
Address  OPD 208, Hospital block, All India Institute of Ayurveda, Gautampuri, Sarita Vihar All India Institute of Ayurveda, Gautampuri, Sarita Vihar South West DELHI 110076 India

South West
DELHI
110076
India 
Phone  8368150104  
Fax    
Email  jitu.acharya91@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Rajagopala Shrikrishna 
Designation  Associate Professor 
Affiliation  All India Institute of Ayurveda 
Address  Room no. 403, 4th floor Academic block, All India Institute of Ayurveda, Gautampuri, Sarita Vihar All India Institute of Ayurveda, Gautampuri, Sarita Vihar South West DELHI 110076 India

South West
DELHI
110076
India 
Phone  7600902564  
Fax    
Email  srajagopala@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Rajagopala Shrikrishna 
Designation  Associate Professor 
Affiliation  All India Institute of Ayurveda 
Address  Room no. 403, 4th floor Academic block, All India Institute of Ayurveda, Gautampuri, Sarita Vihar All India Institute of Ayurveda, Gautampuri, Sarita Vihar South West DELHI 110076 India

South West
DELHI
110076
India 
Phone  7600902564  
Fax    
Email  srajagopala@gmail.com  
 
Source of Monetary or Material Support  
All india institute of Ayurveda 
All india institute of Ayurveda,gautampuri,sarita vihar,nearmohan estate metro station,New Delhi 110076 
 
Primary Sponsor  
Name  All India Institute of Ayurveda 
Address  Saritavihar, Gautampuri New Delhi 110076 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
dr Rajagopala Srikrishna  All india institute of ayurveda  All india institute of ayurveda,gautampuri,sarita vihar,new delhi 110076
South West
DELHI 
7600902564

srajagopala@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional ethics committee   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: J454||Moderate persistent asthma,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Shwasahara mahakashaya avleha  Age in years Drug doses in 3 doses 5-7 6gm 8-10 9gm 11-13 12gm 14-15 15gm ORALLY  
Comparator Agent  shwashahara mahakashaya choorna  Age in year Drug dose in 2 divided doses 5-7 4gm 8-10 6gm 11-13 8gm 14-15 10gm ROUTE-ORALLY 
 
Inclusion Criteria  
Age From  5.00 Year(s)
Age To  15.00 Year(s)
Gender  Both 
Details  1) Individuals of either gender between age group of 5 to 15 years.
2) Diagnosed cases of Tamaka Shwasa –bronchial asthma with at least 3 episodes of asthma symptoms (cough, breathlessness) during the previous year.
3) Severity as mild to moderate stable bronchial asthma (Tamaka Shwasa) as per W.H.O GINA Guidelines.
4) Patient on other drug therapy will be included only after completion of the washout period of 3 weeks.
5) Parents giving consent to participate in study.
 
 
ExclusionCriteria 
Details  1. Individuals below 5 years and above 15 years of age.
2. Sever case like status asthmaticus.
3. Evidence of active concomitants pulmonary disease other than asthma.
4. Evidence of requirement of intubation for asthma, or had been hospitalized for asthma within 1 month before. Had unresolved sinus disease or an unresolved upper or lower respiratory tract infection within 3 weeks. 5. More than 4 short courses of oral corticosteroids within the year preceding the screening visit or any oral corticosteroids in the preceding 4 weeks.
6. Concomitant severe decompensated systemic disease (cardiovascular, renal, hepatic, endocrine, haematological, neurological, immunological).
7. Patient/Parents not willing to participate in the study.

 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
1. Improvement in classical sign and symptoms of Tamaka Shwasa.
2.Decrease in frequency, duration and severity of attacks.  
0 day,15th day,30th day,45th day60th day 
 
Secondary Outcome  
Outcome  TimePoints 
1-Asthma control questionaire
2-GINA asthma guidelines
3-Ayurvedic parameters like Dasavidha parikshya,Astasthana parikshya
4-pulmonary function test and peak expiratory flow examination 
oday,60 day an one during follow up 
1-Asthma control questionaire
2-GINA asthma guidelines
3-Ayurvedic parameters like Dasavidha parikshya,Astasthana parikshya
4-pulmonary function test and peak expiratory flow examination 
oday,60 day an one during follow up 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   28/06/2019 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   outcomes will be published in peer journals for wider dissemination  
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

.

On the basis of their clinical manifestation. Tamaka Shwasa is as described in Ayurveda can be correlated with the disease bronchial asthma of modern medical science [1].

Bronchial asthma is characterized by chronic airway inflammation and increased airway.

Bronchial asthma is characterized by chronic airway inflammation and increased airway responsiveness resulting in symptoms of wheeze, cough, chest tightness and dyspnoea. It is also functionally characterized by the air flow limitations which usually reverse spontaneously or with treatments. 

The prevalence of bronchial asthma has increased continuously since the 1970 and now effects 4-7% of the people worldwide[2]. There has been increase in the prevalence, and a similar trend is observed in India. Asthma prevalence rate in some states of India like Karnataka, Gujarat, Hariyana, Uttar Pradesh, Madhya Pradesh are above the national level[3]. The disease is more predominant in children and aged population. At the age of 6-7 years the prevalence ranges from 4%-32% apart from being the leading cause of hospitalization for children, it is one of the most important chronic condition causing elementary school absenteeism[4,5]. 

There is limited information on the various modalities of Ayurvedic management on Tamaka Shwasa  i.e. Bronchial Asthma especially in children. The treatment principles of Tamaka Shwasa as described in our classical texts includes Shodhana, Shamana, herbal and herbominerals compound. In Charaka Samhita, It contributes several modalities of the treatment for Shwasa roga (asthma). Among all modalities of treatment, polyherbal combinations are said to be well-accepted, safe and effective in asthma. Maharsi Charaka described 10 drugs in Shwasahara Mahakashaya in sutra Sthana [6].

Acharya Charaka has summarized 500 kashayas in 50 Maha kashayas. The Maha kashayas are described with their characteristics. For example-the Maha kashayas which contains jeevaka, jeevanti etc. is termed as jeevaniya mahakashaya. Again these 50 Mahakashaya having classified in 10 groups. The sub classification has been done according to the similarities of name of Mahakashaya. Some group are classified on the basis of its action i.e Mahakashaya useful for panchakarma are grouped into subtypes like Snehopaga, Swedopaga,Vamanopaga etc. Among these, Shwasahara Mahakashaya also contains 10 drugs and is used to treat the condition of Pranavaha Srotas like Tamaka Swasa. The Shwasahara Mahakashaya contains 10 drugs such as – Shati, Puskarmoola, Amalavetas, Ela, Hingu, Agaru, Surasa, Tamalaki, Jeevanti and Chanda.OBJECTIVES OF THE RESEARCH PROJECT:

 The present research trial has been undertaken with the following objectives.

PRIMARY OBJECTIVES:

ï‚· To assess the efficacy of Shwasahara Mahakashaya in childhood bronchial asthma

SECONDARY OBJECTIVE: - 

ï‚· To assess the improvement in quality of life of children and parents.

METHODOLOGY:

Patients will be randomly selected from OPD of age group 5-15 years. The children coming under the inclusion criteria of the study and their parents will be counselled and informed about the treatment plan. Those who are willing to undergo the therapy and ready to submit informed consent shall be recruited in the proposed clinical study. The selected subjects will be randomly divided into two groups with the help of computer generated randomization table.

CLINICAL STUDY:

Study type

Interventional, Comparative, Superiority

Purpose

Treatment

Timing

Prospective

End Point

Efficacy

No. Of groups

Two groups

Sample size

60(30 in each group)

 

SETTING - Clinical study will be conducted in the department of     Kaumarabhritya, All India Institute of Ayurveda, New Delhi.

SIZE AND SAMPLE CALCULATION

As per the study of Neha R. Patel et.al [9], the proven efficacy of Shwasahara Mahakashaya choorna  is 54% and 70% is expected in present study with the level of significance in 95% and power of 80%.the sample size is calculated on this base by using the following formula. Formula for 2 groups

 n =2 (Zα+Zβ)2/ (p0-p1)2 x pq

 Average  sample size will be 144.

 

 

 
Close